Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 3Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb

3Q Revenues: $5.3 billion (+14%)

3Q Earnings: $2.6 billion (earnings were $858 million in 3Q07)

YTD Revenues: $15.3 billion (+17%)

YTD Earnings: $4.0 billion (+74%)

Comments: Pharmaceutical sales were up 15% to $4.5 billion in the quarter. Growth was driven by strong performance from Plavix, Abilify, the HIV and hepatitis portfolio, as well as Orencia. Plavix sales were $1.4 billion in the quarter (+15%). Abilify sales were $564 million (+34%). Sustiva Franchise sales were $294 million (+24%). Reyataz sales were $342 million (+25%). Orencia sales were up 98% to $119 million. Avapro/Avalide sales were $334 million (+8%). Baraclude sales were up 100% to $144 million. Earnings include a $2.0 billion after-tax gain attributed to the sale of the company’s ConvaTec business. R&D expenses were up 4% to $834 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters